Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVIE: Metronomic Vinorelbine + Durvalumab + Tremelimumab in Advanced Solid Tumors
NCT03518606Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jun 2018
- Primary completion
- Apr 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of vinorelbine, durvalumab and tremelimumab in breast cancer, head and neck squamous cell carcinoma (HNSCC), Cervical Cancer (CC) and 2 more (5 cohorts), sponsored by Unicancer. Primary endpoints: Maximum Tolerated Dose at 9 months, Recommended Phase 2 Dose at 9 months and 1 more. Started Jun 2018; status: completed.
02
Drugs
vinorelbinedurvalumabtremelimumab
03
Conditions
breast cancerhead and neck squamous cell carcinoma (HNSCC)Cervical Cancer (CC)prostate cancer (PCa)solid tumor
Beyond the preview
Go deeper on NCT03518606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03518606.